Evidence map›Paper›PMID 41009564›Full record

ArticleInternational journal of molecular sciences2025

The Association Between Genetics and Response to Treatment with Biologics in Patients with Psoriasis.

Nikolai Loft, Sule Altintas, Rownaq Al-Sofi, Daniel Isufi, Claus Zachariae, Diljit Kaur-Knudsen, Claus Henrik Nielsen, Lone Skov

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nikolai LoftDepartment of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, 2900 Hellerup, Denmark.ORCID 0000-0002-2950-3280
Sule AltintasDepartment of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, 2900 Hellerup, Denmark.ORCID 0009-0004-5902-2842
Rownaq Al-SofiDepartment of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, 2900 Hellerup, Denmark.
Daniel IsufiDepartment of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, 2900 Hellerup, Denmark.ORCID 0009-0003-2780-3604
Claus ZachariaeDepartment of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, 2900 Hellerup, Denmark.
Diljit Kaur-KnudsenDepartment of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, 2900 Hellerup, Denmark.
Claus Henrik NielsenInstitute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
Lone SkovDepartment of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, 2900 Hellerup, Denmark.ORCID 0000-0002-4784-9680

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biologics targeting tumor necrosis factor-α (TNFi), interleukin-12/23 (IL-12/23i), and interleukin-17 cytokine or receptor (IL-17i/IL-17Ri) have transformed psoriasis management. However, interindividual variation in response underscores the need for predictive biomarkers in guiding therapy selection. Patients treated with a biologic for psoriasis were genotyped for 67 single-nucleotide polymorphisms (SNPs) previously associated with response to biologics. Odds ratios (OR) with 95% confidence intervals (CI) for associations between SNPs and response to biologics were calculated using logistic regression models with an absolute Psoriasis Area and Severity Index (PASI) ≤2 after 3 months as treatment response. A

Indexed as

Biological ProductsPolymorphism, Single NucleotidePsoriasisAdultAgedFemaleGenotypeHumansInterleukin-12Interleukin-1 Receptor-Associated KinasesMaleMiddle AgedTreatment OutcomeTumor Necrosis Factor-alphaBiological ProductsInterleukin-12Interleukin-1 Receptor-Associated KinasesTumor Necrosis Factor-alphaadalimumabbiologicsbrodalumabgeneticsixekizumabpharmacogeneticspsoriasissecukinumabustekinumab

Identifiers

PMID41009564
PMCPMC12469637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.